Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.07.06
- Author:
Sixuan WU
1
;
Chunhong HU
1
;
Fang WU
1
;
Yuanqiang WU
1
;
Ping LIU
1
Author Information
1. Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, China.
- Publication Type:Journal Article
- Keywords:
Cancer immunotherapy;
Immune checkpoint inhibitor;
Lung neoplasms;
PD-1/PD-L1
- From:
Chinese Journal of Lung Cancer
2019;22(7):440-448
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of NSCLC and changed the treatment pattern for NSCLC. Immunological checkpoint inhibitors targeting PD-1/PD-L1 are beneficial to patients, both in the first-line and second-line treatment of advanced NSCLC, in the adjuvant treatment of locally-advanced NSCLC, and in the neoadjuvant therapy of early NSCLC, which show an important role in the comprehensive treatment of NSCLC. This article reviews the clinical research progress of immunological checkpoint inhibitors targeting PD-1/PD-L1 in NSCLC.
.
